Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Page 1
Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors.
Cancers (Basel). 2022 Dec 11;14(24):6101. doi: 10.3390/cancers14246101.
Cancers (Basel). 2022.
PMID: 36551587
Free PMC article.
Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells.
Verdura S, Encinar JA, Fernández-Arroyo S, Joven J, Cuyàs E, Bosch-Barrera J, Menendez JA.
Verdura S, et al.
Int J Mol Sci. 2022 Sep 1;23(17):9986. doi: 10.3390/ijms23179986.
Int J Mol Sci. 2022.
PMID: 36077379
Free PMC article.
Item in Clipboard
Cite
Cite